We have previously described a scoring system for patients undergoing hemopoietic stem cell transplantation (HSCT) based on day +7 blood urea nitrogen (BUN) and serum bilirubin levels. We have revised that scoring system using a formal multivariate approach based on a training phase (305 patients) and a validation phase (217 patients). Day +7 BUN, serum cholinesterase (CHE), total proteins (TP), gamma glutamyl transferase (cGT), donor type and cell dose at transplant were included in the new score. The score distribution identified three groups of patients in the training set (o25, 25-75, 475 percentile of the score) which were classified as low, intermediate and high risk. Their actuarial risk of transplant-related mortality (TRM) at 6 years was, respectively, 12, 38 and 60%. In the validation set the 6 year actuarial TRM was, respectively, 15, 40 and 69%. High risk patients had more graft-versus-host disease (GvHD) (Po0.0001) and lower platelet counts (Po0.0001). This study confirms that GvHD and TRM can be predicted on day +7 after HSCT: pre-emptive GvHD therapy may be one option for high-risk patients and is being tested in a prospective randomized trial. The score for single patients can be calculated on the web site
Over the past decades, we have improved in our ability to prevent and/or treat complications following hemopoietic stem cell transplantation (HSCT). 1 As a result, transplantrelated mortality (TRM) has been reduced and delayed: the 10 percentile in our program is currently day 17, and the 75 percentile is day 290, with very few patients dying before day +7 (unpublished). Several studies have addressed the issue of risk factors for complications such as interstitial pneumonitis, 2 acute GvHD 3,4 graft rejection: 5 patient variables (older age), donor variables (older age, parous female donors for male recipients, degree of HLA matching) and transplant variables (longer interval from diagnosis to transplant, intensive regimens) are among these risk factors. Early increase in bilirubin levels was found to predict fatal veno occlusive disease (VOD) of the liver. 6 We have shown in a previous study that blood urea nitrogen (BUN) and serum bilirubin levels on day +7 post-HSCT identify patients with a different risk of TRM:
7 the low-risk group had a TRM of 20 vs 44 for the high-risk patients (P ¼ 0.0001). 7 We now report a revised day +7 scoring system based on a larger set of patient variables including day +7 cholinesterase (CHE), total protein (TP), gamma glutamyl transferase (gGT), donor type and cell dose at transplant.
Materials and methods

Data collection
Data are recorded prospectively from all patients allografted in our Bone Marrow Transplant Unit, with a patient monitoring program, in operation since 1989, as previously described. 7 
Patients
The entire database contained 618 patients, but only 522 had valid data for all variables. The donor/recipient data (gender, age, diagnosis, outcome) of 96 excluded patients and of the 522 patients included in the analysis were comparable. The detailed characteristics of the 522 patients in the analysis are reported in Table 1 . The graft was unmanipulated in the large majority of patients (93%). A total of 36 patients received marrow T-cell depleted with CAMPATH 1M (kindly provided by G Hale and H Waldman, Cambridge, UK). The conditioning regimen included total body irradiation (TBI) 10-12 Gy in fractionated doses in 360 patients; patients not receiving TBI were given cyclophosphamide (CY) (100-150 mg/kg) and thiotepa (10-15 mg/kg), or CY alone (200 mg/kg). Graft-versushost disease (GvHD) prophylaxis was not given to the 36 TCD patients and five twin transplants. In the remaining patients, it consisted of cyclosporine (CsA) alone or with short course methotrexate (MTX). Transplant protocols and management of patients have been described. 8 Patients were grafted between 18. 1.1990 and 10.3.2000 .
TRM
The aim of this study was to assess the correlation of laboratory tests with TRM, defined as death due to any transplant-related complication. Thus, patients experiencing relapse of the original disease were censored as surviving at the time of relapse. The median time to transplant-related death was 104 days.
Data analysis
A prognostic model must be able to discriminate patients with different prognoses and also to give reliable predictions about the outcome of future patients. The performance of a model on an independent but similar data set to that used to build the model itself is a key feature that makes it possible to assess the predictive ability of the selected model. Our data set is made up of 522 patients with valid data and was split into a 'training' sample, on which a model was developed with standard methods, and a 'validation' sample that was used to validate the model. The training and validation samples were randomly selected from the entire data set in a ratio 3:2.
Step 1. A total of 363 patients were included in the training set. Univariate Cox analyses were carried over to identify variables significantly related to TRM. Variables with a P-value of less than 0.20 were entered into a standard multivariate Cox model, used to select variables independently affecting TRM. A backward selection criterion was used with a P-value for removal of 0.10. The distribution of each continuous independent variable was studied: variables with a skewed distribution were log transformed or were categorized using the 25-75 percentiles. The transformation was chosen according to the maximum likelihood criterion. Once the final model was selected, a score was calculated using the variables included in the model and the estimated coefficients. According to the score distribution, three groups of patients were identified, using arbitrary cutoff values (below 25, 25-75 and above 75 percentile of the score), as low, intermediate and high risk. Kaplan-Meier survival curves and Cox hazard ratios (HR) were estimated for these groups of patients. The proportional hazard assumption necessary to run the Cox model was verified using graphical methods (data not shown).
Step 2. In all, 255 patients were included in the validation set. The score calculated using the coefficient estimated on the training set was tested on the validation set, by examining its ability in discriminating patients at different TRM. Kaplan-Meier survival curves and Cox HR were used to assess model performance.
Step 3. A model was built to predict the risk of TRM in individual patients using the Cox model based formula:
where S x ¼ cumulative survival for patients with score ¼ x; S 0 ¼ cumulative survival for patients with score ¼ 0 (reference level); b ¼ parameter estimated on the validation set; S 0 was estimated using a Kaplan-Meier estimate on the entire data set.
Results
Univariate analysis on the training set using the 25-75 percentiles. Variables with a P-value of less than 0.20 entered the multivariate analysis.
Multivariate COX analysis on the training set
A multivariate COX analysis was carried out including all the patient-related, disease-related and transplant-related variables with a P-value of less than 0.20 on univariate analysis. The final model included 305 patients with complete data. Table 3 shows variables included in the final model: CHE (P ¼ 0.01), TP (P ¼ 0.08), BUN (P ¼ 0.0025), gGT (P ¼ 0.003), donor type (HLA identical/alternative) (P ¼ 0.001) and cell dose (P ¼ 0.04). Year of transplant was used as a stratification variable. Using the coefficient estimated by the model (Table 3) , a scoring system was calculated for each patient: Figure 1a outlines the Kaplan-Meier curves, for patients in the training set with low, intermediate and high scores, as identified by the 25-75 percentiles. The TRM at 6 years was 12% (s.e. ¼ 0.04), 38% (s.e. ¼ 0.06) and 60% (s.e. ¼ 0.07) for the three risk groups, respectively .
Day +7 score distribution in the training set of patients
The score calculated on the training set of patients has a mean value of 0.04 (s.d. ¼ 0.82) and a median of À0.03 (range ¼ À2.31-2.32). To have an estimate of the scoring system sensitivity (specificity cannot be calculated for censored data), we report the number of transplant-related death for each risk group according to this scoring system in Table 5 . In the low-risk group, we found 8% of all Day +7 predictive score for transplant-related mortality MP Sormani et al transplant-related deaths, in the medium-risk group we found 48% and in the high-risk group 44% of all deaths.
Outcome in the training set of patients
The incidence of severe acute GvHD (grades III-IV) was 8, 9 and 23% (P ¼ 0.004) in patients with low , intermediate and high risk. Extensive chronic GvHD developed in 3, 4 and 13% of patients surviving 100 days in the three groups (P ¼ 0.02). In addition high-risk patients had significantly lower platelet counts on days +50, +100, +200 after HSCT ( Figure 2 (Figure 3 ).
Analyses on the validation set
The score calculated on the training set was tested on a validation set of 217 patients with complete data. Transplant mortality curves of the three groups were constructed using the same cutoffs as in the training set (Figure 1b) . Actuarial TRM at 6 years was 15% (s.e. ¼ 0.06), 40% (s.e. ¼ 0.06) and 69% (s.e. ¼ 0.07) for the three risk groups, respectively. This result indicates the robustness and stability of the fitted model, as its ability to discriminate patients with different prognoses is almost identical on a different set of similar subjects. In fact, the coefficients computed on the validation set were similar to those estimated on the training set. In the Appendix, the procedure for predicting TRM for a single new patient undergoing HSCT using laboratory data on day +7 from HSCT is applied to real patient data.
Day +7 score distribution in the validation set of patients
The score calculated on the validation set of patients has a mean value of 0.07 (s.d. ¼ 0.88) and a median of 0.12 (range ¼ À1.84-2.53). As reported in Table 5 , in the lowrisk group (according to this scoring system) we found 9% of all transplant-related deaths, in the medium-risk group this percentage was 45% and in the high-risk group 47%.
Outcome in the validation set of patients
The incidence of severe acute GvHD (grades III-IV) was 7, 6 and 32% (Po0.0001) in patients with low, intermediate and high risk. Extensive chronic GvHD developed in 6, 7 and 7% of patients surviving 100 days in the three groups (P ¼ 0.9). Platelet counts were significantly lower in highrisk patients at different time points after transplant ( Figure 2 ). As to causes of failure, 6, 9 and 20% of patients died of GvHD in the low-, intermediate-and high-risk group; 4, 19 and 29% died of infections; 4, 6 and 11% died of interstitial pneumonia; 2, 4 and 4% died of other transplant-related causes; and 17, 19 and 7% died of recurrent disease (P ¼ 0.0008) (Figure 3 ). 
Prediction of risk of TRM
Discussion
We have shown that a scoring system, with strong predictive power on transplant outcome, can be constructed using day +7 CHE, gGT, TP, BUN together with donor type and cell dose. This conclusion is based on multivariate analysis in a training set of 305 patients, and was confirmed on a validation set of 217 patients, all undergoing allogeneic HSCT. We already published a scoring system based on day +7 bilirubin and day +7 BUN in 1999:
7 in the present analysis, BUN remained a very significant predictor, whereas CHE and gGT proved to be superior to bilirubin and the latter was excluded from the final model. The variables now include liver function tests (CHE and gGT), a renal function test (BUN), total serum protein as an indicator of intestinal integrity and synthetic capacity, cell dose and donor type. Although the latter are pretransplant variables, their inclusion added power to the predictive score. The combination of cell dose and donor type with the four laboratory tests identifies patients with different risks of TRM, ranging from 15% for low-risk, to 40% in the intermediate-risk and 69% in the high-risk group.
On univariate analysis, a number of variables were predictive for TRM, including bilirubine, alkaline phosphatase, albumin and donor age, which were, however, excluded from the multivariate final model. The year of transplant was not predictive for two reasons: (a) all patients were grafted after 1990, in which time period there has been less improvement, as compared to a previous significant reduction of TRM, 1 and (b) the proportion of alternative donor transplants has increased from 7% before 1993 to 49% beyond 1997. Patient age was not significant on univariate analysis because the outcome is confounded by unrelated transplants being performed in younger patients; however, if one enters age as a predictor in HLA identical siblings only, then it is highly significant (Po0.0001). If one runs a COX analysis with patients age and donor type together, they are both significant: however, if one runs the analysis with age and day +7 score, the patient age is no longer significant (P ¼ 0.3). In other words, day +7 score outweighs patient age, which is a well-known predictor of TRM. It must therefore be that the indicators identified in our model, such as CHE, BUN, gGT and total serum protein, on day +7 after transplant are stronger than the generic age assessment, possibly because they are influenced by early post-transplant events. In this analysis, we had 112 patients over 45 years of age, of whom 21 were scored as low risk (TRM 14%), 63 as intermediate risk (TRM 27%) and 28 as high risk (TRM is associated with a greater risk of death due to GvHD, infections, interstitial pneumonitis and other transplant-related causes (Po0.001). The risk of dying of leukemia relapse is conversely reduced.
50%) (P ¼ 0.01). In keeping with the observation that our day +7 score could predict different risks of TRM in older patients, this was true also when testing the scoring system in subsets of patients, such as sibling or alternative donor transplants, grafted with or without TBI, patients with early, or advanced disease, patients grafted before or after 1995, and finally patients receiving unmanipulated or T-cell depleted grafts. As to the latter, CAMPATH did not abrogate GvHD completely, and high-risk patients had more GvHD (P ¼ 0.05).
We were particularly impressed with the prognostic value of CHE, recently shown to be a very significant predictor of GvHD and outcome. 9 This is possibly due to the fact that liver complications are frequent following allogeneic HSCT 10 and serum CHE is a sensitive predictor of outcome in patients with liver disease. 11, 12 gGT is also a sensitive marker of liver disease, and was selected as an independent predictor of TRM in the multivariate COX analysis.
The strong impact of BUN on TRM, is possibly a correlate of early renal insufficiency. One could argue that BUN is sensitive to dehydration, which may occur in patients after transplantation, and we therefore analyzed creatinine levels in more detail. The median BUN of all patients on day +7 is 22 mg/dl, and the proportion of patients with BUN levels greater than 22 mg/dl is 18, 43 and 69% in the three risk groups, respectively (Po0.00001). Similarly, median creatinine is 0.8 mg/dl and the proportion of patients with levels greater than 0.8 mg/dl is 20, 35 and 56% (Po0.00001) in the same three groups. Therefore, patients with a high-risk score on day +7 do have subclinical renal insufficiency, in keeping with the fact that renal involvement after HSCT is a frequent event. 13 The present study would suggest that (a) the degree of impairment of renal function strongly correlates with the outcome of the transplant and (b) that BUN is an early marker of both renal impairment and acute GvHD, more sensitive than creatinine (which was not selected by the model).
When looking at the causes of death, patients with a high score were at greater risk of dying of GvHD, infections, interstitial pneumonia and multiorgan failure. These complications are often correlated, as suggested by interstitial pneumonitis developing only in animals given TBI and allogeneic T cells, as opposed to animals given TBI and syngeneic T cells. 14 Whatever the pathogenetic interpretation, the practical consequence is that these early predictors can be picked up a few days after one conditioning and after donor T cells have been infused into the patient, that is day +7. By then, modifications of CHE, gGT, BUN and TP are indicating the degree of organ damage and/or alloreactivity which would otherwise not be diagnosed. Indeed, in the experimental model, 15 relevant cellular interactions and organ damage seem to have already taken place in the first week post-transplant, and consequently, on day +7, the fate of the transplant is already set to a large extent.
The next important question concerns the usefulness of early identification of GvHD. We do not know at present whether the outcome of high-risk patients can be changed on day +7 by medical intervention. However, several treatment modifications could be made in high-risk patients: these may include increased immunosuppression, or other supportive measures such as more intensive parenteral nutrition, early antibacterial and/or anti-fungal therapy. Pre-emptive treatment of GvHD with anti-T-cell antibodies was shown to be effective in HLA-identical sibling transplants many years ago, 16 and more recently in alternative donor transplants. 17 A trial of pre-emptive GvHD therapy may be one option and is being tested in a prospective randomized trial.
